<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04909073</url>
  </required_header>
  <id_info>
    <org_study_id>1200.0303</org_study_id>
    <nct_id>NCT04909073</nct_id>
  </id_info>
  <brief_title>Observational Study of Afatinib 30 mg Daily</brief_title>
  <official_title>An Observational Study of Afatinib 30 mg Daily in Patients With Advanced Non-small Cell Lung Cancer (NSCLC) Harbouring Common EGFR Mutations Treated With Afatinib</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National University Hospital, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>National University Hospital, Singapore</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Afatinib, a first-in-class irreversible ErbB family blocker, is a 1st line treatment option&#xD;
      for patients with advanced stage NSCLC harbouring sensitizing EGFR mutations. In randomized&#xD;
      1st line studies of afatinib at a standard dose of 40 mg daily versus standard of care,&#xD;
      28-53% of patients required a dose reduction due to adverse events (AE) induced by afatinib.&#xD;
      The most common AEs are cutaneous and gastrointestinal (diarrhoea, dysphagia, and mucositis).&#xD;
      Prevalence of diarrhoea in patients receiving 40 mg of afatinib, in 1st line phase II and III&#xD;
      studies is as high as 90.0% (all grades of diarrhoea) and 14.4% (grade 3-4 diarrhoea).&#xD;
      Another important gastrointestinal AE is mucositis, which presents in 51.9%-64.4% of patients&#xD;
      treated with afatinib, with only 4.4%-8.3% of the cases being grade 3-4. Dose reduction&#xD;
      tended to occur in patients who had higher initial afatinib plasma concentrations and led to&#xD;
      decreases in the incidence and severity of afatinib-related AEs without affecting therapeutic&#xD;
      efficacy. The incidence of gastrointestinal AEs could be decreased &gt;50% with proper afatinib&#xD;
      dose reduction.&#xD;
&#xD;
      The effect of 1st line afatinib 30 mg daily in patients with EGFR mutation-positive NSCLC is&#xD;
      unknown. We hypothesize that, in patients with EGFR mutation-positive NSCLC, 1st line&#xD;
      afatinib treatment at 30 mg daily is tolerable with less gastrointestinal AEs and with a&#xD;
      similar efficacy to standard dose afatinib.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a multi-country, multi-centre, study designed to collect clinical data and to&#xD;
      evaluate efficacy and safety of patients treated with afatinib 30 mg at the Investigator's&#xD;
      discretion.&#xD;
&#xD;
      All entered patients (i.e., patients that have been treated with the defined medication) will&#xD;
      receive continuous treatment of afatinib in the absence of disease progression or meeting any&#xD;
      other withdrawal criteria. All patients will visit Investigator at regular intervals for&#xD;
      assessment of efficacy and safety as outlined in the Flow Chart for the first 7 cycles&#xD;
      treatment. The Investigator will assess the patient at each visit. Tumour response and&#xD;
      progression will be assessed using RECIST 1.1 at the Investigator site.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">December 2021</start_date>
  <completion_date type="Anticipated">December 2024</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Progression-free survival rate</measure>
    <time_frame>6 months</time_frame>
    <description>To assess the effect of afatinib 30 mg daily at the Investigator's discretion on progression-free survival rate (PFSR) at month 6.</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">69</enrollment>
  <condition>Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor</condition>
  <arm_group>
    <arm_group_label>Afatinib 30 mg daily</arm_group_label>
    <description>Oral afatinib 30 mg tablet once daily, continuously</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Afatinib</intervention_name>
    <description>Continuous treatment of afatinib 30mg tablet once daily in the absence of disease progression or unacceptable treatment-related toxicity, Investigator decision or patient decision to discontinue study treatment.</description>
    <arm_group_label>Afatinib 30 mg daily</arm_group_label>
    <other_name>Giotrif</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients who has taken 30 mg Afatinib as initial dose and still on treatment for less than&#xD;
        28 days&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥18 years.&#xD;
&#xD;
          2. ECOG performance status 0-1.&#xD;
&#xD;
          3. Pathologically confirmed diagnosis of Stage IIIB/IV adenocarcinoma of the lung.&#xD;
&#xD;
          4. Have been commenced on first line afatinib 30 mg within 4 weeks of study enrolment.&#xD;
&#xD;
          5. Documented EGFR mutation(s)-positive NSCLC (common mutations: Del19 and L858R) from&#xD;
             tumour biopsy material. Results of EGFR mutation test must be available before taking&#xD;
             Afatinib.&#xD;
&#xD;
          6. A CT thorax/ abdomen within 4 weeks of study enrolment with at least one measurable&#xD;
             lesion according to the Response Evaluation Criteria in Solid Tumours (RECIST) version&#xD;
             1.1.&#xD;
&#xD;
          7. No brain metastases (confirmed by a CT or MRI brain performed within 4 weeks of study&#xD;
             enrolment)&#xD;
&#xD;
          8. Documented adequate organ function before taking Afatinib:&#xD;
&#xD;
               -  Absolute neutrophil count (ANC) ≥1500/mm3. (ANC &gt;1000/mm3 may be considered in&#xD;
                  special circumstances such as benign cyclical neutropenia as judged by the&#xD;
                  Investigator and in discussion with the sponsor-Investigator).&#xD;
&#xD;
               -  Platelet count ≥75,000/mm3.&#xD;
&#xD;
               -  Estimated creatinine clearance using Cockcroft Gault calculation of at least 45&#xD;
                  ml/min.&#xD;
&#xD;
               -  Total Bilirubin ≤1.5 times upper limit of (institutional/central) normal&#xD;
                  (Patients with Gilbert's syndrome total bilirubin must be ≤4 times institutional&#xD;
                  upper limit of normal).&#xD;
&#xD;
               -  Aspartate amino transferase (AST) or alanine amino transferase (ALT) ≤3 times the&#xD;
                  upper limit of (institutional/central) normal (ULN) (if related to liver&#xD;
                  metastases ≤5 times ULN).&#xD;
&#xD;
          9. Archived tissue sample is available.&#xD;
&#xD;
         10. Written informed consent per regulations.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Prior chemotherapy for Stage IIIB/IV adenocarcinoma of the lung. Neo-/adjuvant&#xD;
             chemotherapy, CT-RT or RT is permitted if it has been elapsed for =12 months prior to&#xD;
             disease progression.&#xD;
&#xD;
          2. Prior treatment with EGFR targeting small molecules or antibodies.&#xD;
&#xD;
          3. Major surgery within 4 weeks of study treatment.&#xD;
&#xD;
          4. Brain metastases.&#xD;
&#xD;
          5. Meningeal carcinomatosis.&#xD;
&#xD;
          6. Known pre-existing interstitial lung disease (ILD).&#xD;
&#xD;
          7. Patients with a significant disease other than lung cancer; a significant disease is&#xD;
             defined as a disease which, in the opinion of the investigator, may:&#xD;
&#xD;
               -  put the patient at risk because of participation in the study&#xD;
&#xD;
               -  influence the results of the study&#xD;
&#xD;
               -  cause concern regarding the patient's ability to participate in the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Nationa University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <results_reference>
    <citation>Tan DS, Yom SS, Tsao MS, Pass HI, Kelly K, Peled N, Yung RC, Wistuba II, Yatabe Y, Unger M, Mack PC, Wynes MW, Mitsudomi T, Weder W, Yankelevitz D, Herbst RS, Gandara DR, Carbone DP, Bunn PA Jr, Mok TS, Hirsch FR. The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016. J Thorac Oncol. 2016 Jul;11(7):946-63. doi: 10.1016/j.jtho.2016.05.008. Epub 2016 May 23. Review.</citation>
    <PMID>27229180</PMID>
  </results_reference>
  <results_reference>
    <citation>Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, Geater SL, Orlov S, Tsai CM, Boyer M, Su WC, Bennouna J, Kato T, Gorbunova V, Lee KH, Shah R, Massey D, Zazulina V, Shahidi M, Schuler M. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. J Clin Oncol. 2013 Sep 20;31(27):3327-34. doi: 10.1200/JCO.2012.44.2806. Epub 2013 Jul 1.</citation>
    <PMID>23816960</PMID>
  </results_reference>
  <results_reference>
    <citation>Yang JC, Wu YL, Schuler M, Sebastian M, Popat S, Yamamoto N, Zhou C, Hu CP, O'Byrne K, Feng J, Lu S, Huang Y, Geater SL, Lee KY, Tsai CM, Gorbunova V, Hirsh V, Bennouna J, Orlov S, Mok T, Boyer M, Su WC, Lee KH, Kato T, Massey D, Shahidi M, Zazulina V, Sequist LV. Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials. Lancet Oncol. 2015 Feb;16(2):141-51. doi: 10.1016/S1470-2045(14)71173-8. Epub 2015 Jan 12.</citation>
    <PMID>25589191</PMID>
  </results_reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>May 26, 2021</study_first_submitted>
  <study_first_submitted_qc>May 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 1, 2021</study_first_posted>
  <last_update_submitted>May 26, 2021</last_update_submitted>
  <last_update_submitted_qc>May 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>afatinib</keyword>
  <keyword>EGFR mutation-positive NSCLC</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Afatinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

